Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author van der Horst, Marte Z.
• dc.contributor.author Meijer, Yoeki
• dc.contributor.author de Boer, Nini
• dc.contributor.author Guloksuz, Sinan
• dc.contributor.author Hasan, Alkomiet
• dc.contributor.author Siskind, Dan
• dc.contributor.author Wagner, Elias
• dc.contributor.author CLOZIN consortium
• dc.contributor.author Okhuijsen-Pfeifer, Cynthia
• dc.contributor.author Luykx, Jurjen J.
• dc.date.accessioned 2024-11-06T07:17:03Z
• dc.date.available 2024-11-06T07:17:03Z
• dc.date.issued 2023
• dc.description.abstract Clozapine is often underused due to concerns about adverse drug reactions (ADRs) but studies into their prevalences are inconclusive. We therefore comprehensively examined prevalences of clozapine-associated ADRs in individuals with schizophrenia and demographic and clinical factors associated with their occurrence. Data from a multi-center study (n = 698 participants) were collected. The mean number of ADRs during clozapine treatment was 4.8, with 2.4 % of participants reporting no ADRs. The most common ADRs were hypersalivation (74.6 %), weight gain (69.3 %), and increased sleep necessity (65.9 %), all of which were more common in younger participants. Participants with lower BMI prior to treatment were more likely to experience significant weight gain (>10 %). Constipation occurred more frequently with higher clozapine blood levels and doses. There were no differences in ADR prevalence rates between participants receiving clozapine monotherapy and polytherapy. These findings emphasize the high prevalence of clozapine-associated ADRs and highlight several demographic and clinical factors contributing to their occurrence. By understanding these factors, clinicians can better anticipate and manage clozapine-associated ADRs, leading to improved treatment outcomes and patient well-being.
• dc.format.mimetype application/pdf
• dc.identifier.citation van der Horst MZ, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, et al. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Res. 2023 Dec;330:115539. DOI: 10.1016/j.psychres.2023.115539
• dc.identifier.doi http://dx.doi.org/10.1016/j.psychres.2023.115539
• dc.identifier.issn 0165-1781
• dc.identifier.uri http://hdl.handle.net/10230/68444
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Psychiatry Res. 2023 Dec;330:115539
• dc.rights © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Antipsychotics
• dc.subject.keyword Schizophrenia
• dc.subject.keyword Side-effects
• dc.subject.keyword Treatment-resistant schizophrenia
• dc.title Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion